Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.57 |
| ▸ | RAB9A | P51151 | 8/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | PLAU | P00749 | 4/20 | 0.54 |
| ▸ | PLG | P00747 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13709595 | 0.84 | HDAC1 (0.74) | NPC1RAB9AHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13709512 | 0.79 | F9 (0.56) | CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL7318967 | 0.78 | PLAU (0.72) | NPC1RAB9AHDAC1PLAUPLG | |
| SCHEMBL6508477 | 0.78 | HDAC1 (0.71) | NPC1RAB9AHDAC1TP53SMN1; SMN2 | |
| SCHEMBL7320266 | 0.77 | PLAU (0.65) | NPC1RAB9AHDAC1ALDH1A1PLAU | |
| SCHEMBL13709548 | 0.76 | HDAC1 (0.70) | NPC1RAB9AHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1886161 | 0.76 | HDAC1 (0.67) | NPC1RAB9AHDAC1TP53SMN1; SMN2 | |
| SCHEMBL13709559 | 0.75 | HDAC1 (0.54) | NPC1RAB9AHDAC1PLAUPLG | |
| SCHEMBL13709530 | 0.75 | HDAC1 (0.74) | NPC1RAB9AHDAC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13709655 | 0.75 | CA2 (0.56) | HDAC1ALDH1A1PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | TRIGEN LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221564-A1 | Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease | F12, F5, F3 | NPC1 3342/4885RAB9A 1135/4885HDAC1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.